COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT

被引：0
|
作者：
Vorobyev, P. [1 ]
Krasnova, L. [2 ]
Borisenko, O. [1 ]
Lukyantseva, D. [2 ]
Bashlakova, L. [2 ]
机构：
[1] Russian Soc Pharmacoecon & Outcomes Res, Moscow, Russia
[2] Moscow State Med Univ, Moscow, Russia
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A41 / A41
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT
    Vorobyev, P.
    Krasnova, L.
    Borisenko, O.
    Lukyantseva, D.
    Bashlakova, E.
    VALUE IN HEALTH, 2011, 14 (03) : A40 - A40
  • [2] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP AND KNEE REPLACEMENT IN EUROPE
    Monreal, M.
    Ryttberg, L.
    Diamantopoulos, A.
    Lees, M.
    Negrini, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 50 - 51
  • [3] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) AFTER TOTAL KNEE REPLACEMENT (TKR) IN CHINA
    Chen, X. B.
    Wang, C. Y.
    Eggington, S.
    Zhu, M.
    VALUE IN HEALTH, 2010, 13 (07) : A506 - A506
  • [4] COST-EFFECTIVENESS OF APIXABAN AND ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT IN CHINA
    Yan, X. Y.
    Gu, X. H.
    Bu, J.
    Lin, H. W.
    Wu, B.
    VALUE IN HEALTH, 2016, 19 (07) : A651 - A651
  • [5] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) AFTER TOTAL HIP AND KNEE REPLACEMENT (THR, TKR) IN CHINESE PATIENTS
    Chen, X. B.
    Eggington, S.
    Wang, C. Y.
    Zhu, M.
    VALUE IN HEALTH, 2010, 13 (07) : A520 - A520
  • [6] Pharmacoeconomic Evaluation of Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement in Spain
    Gomez-Outes, Antonio
    Avendano-Sola, Cristina
    Isabel Terleira-Fernandez, Ana
    Vargas-Castrillon, Emilio
    PHARMACOECONOMICS, 2014, 32 (09) : 919 - 936
  • [7] Pharmacoeconomic Evaluation of Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement in Spain
    Antonio Gómez-Outes
    Cristina Avendaño-Solá
    Ana Isabel Terleira-Fernández
    Emilio Vargas-Castrillón
    PharmacoEconomics, 2014, 32 : 919 - 936
  • [8] COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN ETEXILATE VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
    Fernandes, R. A.
    Quintella, F. F.
    Teich, V. D.
    VALUE IN HEALTH, 2009, 12 (07) : A502 - A503
  • [9] COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN IN PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT IN SLOVAKIA
    Lukac, M.
    Bielik, J.
    Lees, M.
    Foltan, V
    Tomek, D.
    VALUE IN HEALTH, 2010, 13 (07) : A520 - A520
  • [10] Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada
    Diamantopoulos, Alexander
    Lees, Michael
    Wells, Philip S.
    Forster, Fiona
    Ananthapavan, Jaithri
    McDonald, Heather
    THROMBOSIS AND HAEMOSTASIS, 2010, 104 (04) : 760 - 770
12345